|
gptkbp:instanceOf
|
gptkb:recreational_drug
gptkb:benzodiazepine
|
|
gptkbp:approvalYear
|
1981
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N05BA12
|
|
gptkbp:brand
|
gptkb:Alprax
gptkb:Niravam
gptkb:Xanax
|
|
gptkbp:CASNumber
|
28981-97-7
|
|
gptkbp:category
|
gptkb:sedative
gptkb:muscle_relaxant
gptkb:benzodiazepine
gptkb:anticonvulsant
|
|
gptkbp:chemicalClass
|
triazolobenzodiazepine
|
|
gptkbp:contraindication
|
acute narrow-angle glaucoma
itraconazole use
ketoconazole use
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:developedBy
|
gptkb:Upjohn
|
|
gptkbp:discoveredBy
|
gptkb:Upjohn
|
|
gptkbp:eliminationHalfLife
|
11 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstSynthesized
|
1971
|
|
gptkbp:hasMolecularFormula
|
C17H13ClN4
|
|
gptkbp:interactsWith
|
gptkb:beer
opioids
other CNS depressants
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Pfizer
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor positive allosteric modulator
|
|
gptkbp:meltingPoint
|
228°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
2033
2118
|
|
gptkbp:riskFactor
|
abuse
overdose
dependence
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
addiction
fatigue
drowsiness
impaired coordination
memory impairment
withdrawal symptoms
|
|
gptkbp:solubility
|
slightly soluble in water
|
|
gptkbp:UNII
|
YW7N9M0A4I
|
|
gptkbp:usedFor
|
gptkb:generalized_anxiety_disorder
gptkb:panic_disorder
anxiety disorders
|
|
gptkbp:bfsParent
|
gptkb:Schedule_IV
gptkb:Benzodiazepines
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Alprazolam
|